Table 2.
Univariate analysis results of progression-free survival in in 97 locally advanced esophageal squamous cell carcinoma patients who received curative concurrent chemoradiotherapy
| Characteristics | No. of patients | Median PFS (months) | P value |
|---|---|---|---|
| Age | |||
| < 60 years | 64 (66%) | 15.6 | 0.044a |
| ≥ 60 years | 33 (34%) | 11.5 | |
| T status | |||
| 1 + 2 | 15 (16%) | 19.1 | 0.35 |
| 3 + 4 | 82 (84%) | 11.9 | |
| N status | |||
| 0 + 1 | 32 (33%) | 20.3 | 0.38 |
| 2 + 3 | 65 (67%) | 11.9 | |
| Stage | |||
| II + IIIA + IIIB | 31 (32%) | 16.5 | 0.93 |
| IIIC | 66 (68%) | 11.5 | |
| Grade | |||
| 1 + 2 | 71 (73%) | 13.3 | 0.49 |
| 3 | 26 (27%) | 14.0 | |
| Location | |||
| Upper | 40 (41%) | 14.6 | 0.76 |
| Middle + Lower | 57 (59%) | 12.3 | |
| VEGF Day 0 (Mean: 176 pg/mL) | |||
| < 80 | 33 (34%) | 14.2 | 0.20 |
| > 80 | 64 (66%) | 13.3 | |
| VEGF Day 5 (Mean: 163 pg/mL) | |||
| < 80 | 33 (34%) | 18.2 | 0.39 |
| > 80 | 64 (66%) | 11.9 | |
| VEGF Day 28 (Mean: 195 pg/mL) | |||
| < 80 | 29 (30%) | 20.1 | 0.029a |
| > 80 | 68 (70%) | 11.5 | |
| VEGF Day 5/Day 0 ratio | |||
| < 1 | 52 (54%) | 15.0 | 0.46 |
| > 1 | 45 (46%) | 10.2 | |
| VEGF Day 28/Day 0 ratio | |||
| < 1 | 39 (40%) | 16.3 | 0.55 |
| > 1 | 58 (60%) | 11.5 | |
| VEGF Day 28/Day 5 ratio | |||
| < 1 | 45 (46%) | 18.5 | 0.029a |
| > 1 | 52 (54%) | 8.2 | |
PFS progression-free survival; VEGF vascular endothelial growth factor; HR hazard ratio; CI confidence interval
aStatistically significant